211 related articles for article (PubMed ID: 27531351)
1. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Blumenthal DT; Dvir A; Lossos A; Tzuk-Shina T; Lior T; Limon D; Yust-Katz S; Lokiec A; Ram Z; Ross JS; Ali SM; Yair R; Soussan-Gutman L; Bokstein F
J Neurooncol; 2016 Oct; 130(1):211-219. PubMed ID: 27531351
[TBL] [Abstract][Full Text] [Related]
2. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.
Howley R; Kinsella P; Buckley PG; Alcock L; Jansen M; Heffernan J; Stallings RL; Brett FM; Amberger-Murphy V; Farrell MA
Exp Cell Res; 2012 Oct; 318(17):2245-56. PubMed ID: 22705586
[TBL] [Abstract][Full Text] [Related]
4. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
5. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
8. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
9. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
10. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathologic diagnosis of epidermal growth factor receptor.
Maire CL; Ligon KL
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii1-6. PubMed ID: 25342599
[TBL] [Abstract][Full Text] [Related]
13. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.
Fernández MB; Alonso VP
Childs Nerv Syst; 2016 Oct; 32(10):1939-45. PubMed ID: 27659836
[TBL] [Abstract][Full Text] [Related]
14. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.
Miklja Z; Yadav VN; Cartaxo RT; Siada R; Thomas CC; Cummings JR; Mullan B; Stallard S; Paul A; Bruzek AK; Wierzbicki K; Yang T; Garcia T; Wolfe I; Leonard M; Robertson PL; Garton HJ; Wahl DR; Parmar H; Sarkaria JN; Kline C; Mueller S; Nicolaides T; Glasser C; Leary SE; Venneti S; Kumar-Sinha C; Chinnaiyan AM; Mody R; Pai MP; Phoenix TN; Marini BL; Koschmann C
J Clin Invest; 2020 Oct; 130(10):5313-5325. PubMed ID: 32603316
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor gene expression in high grade gliomas.
Larysz D; Kula D; Kowal M; Rudnik A; Jarząb M; Blamek S; Bierzyńska-Macyszyn G; Kowalska M; Bażowski P; Jarząb B
Folia Neuropathol; 2011; 49(1):28-38. PubMed ID: 21455841
[TBL] [Abstract][Full Text] [Related]
16. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
[TBL] [Abstract][Full Text] [Related]
17. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
18. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
19. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.
Cimino PJ; Bredemeyer A; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2015 Jun; 98(3):568-73. PubMed ID: 25910966
[TBL] [Abstract][Full Text] [Related]
20. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.
Waha A; Baumann A; Wolf HK; Fimmers R; Neumann J; Kindermann D; Astrahantseff K; Blümcke I; von Deimling A; Schlegel U
J Neurosurg; 1996 Oct; 85(4):634-41. PubMed ID: 8814167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
